These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9760659)

  • 21. A study of schizophrenic outpatients with the Defense Mechanism Test.
    Rubino IA; Pezzarossa B; Ciani N
    Percept Mot Skills; 1991 Oct; 73(2):515-30. PubMed ID: 1766782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personality and defenses: a cross-cultural study of psychiatric patients and healthy individuals in Nicaragua and Sweden.
    Sundbom E; Jacobsson L; Kullgren G; Penayo U
    Psychol Rep; 1998 Dec; 83(3 Pt 2):1331-47. PubMed ID: 10079729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percept-genetic codings of defense in chronic schizophrenia.
    Rubino IA; Verucci M; Savino ML; Hadjichristos A; Saraceni F; Hadjichristos C
    Percept Mot Skills; 1996 Apr; 82(2):483-93. PubMed ID: 8724920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perceptual defense mechanisms in Crohn's disease and panic disorder.
    Rubino IA; Biancone L; Zardo E; Zanna V; Saya A; Ciani N
    Percept Mot Skills; 1999 Jun; 88(3 Pt 1):733-43. PubMed ID: 10407878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signs of defense in obsessive-compulsive disorder: a validation study of the Defense Mechanism Test.
    Rubino IA; Saya A; Siracusano A
    Percept Mot Skills; 2007 Dec; 105(3 Pt 2):1139-42. PubMed ID: 18380111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation of depression and anxiety groups using defense mechanisms.
    Olson TR; Presniak MD; MacGregor MW
    J Nerv Ment Dis; 2009 Nov; 197(11):834-40. PubMed ID: 19996722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrodermal orienting response and central nervous system dopamine and serotonin activity in schizophrenia.
    Ohlund LS; Lindström LH; Ohman A
    J Nerv Ment Dis; 1992 May; 180(5):304-13. PubMed ID: 1374792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of cumulative electrodermal responses in subliminal auditory perception. A preliminary study].
    Borgeat F; Pannetier MF
    Encephale; 1982; 8(4):487-99. PubMed ID: 7151738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contributions of self-defeating philosophies, perceived helplessness, and repression to anxiety among psychiatric patients.
    Watson CG; Vassar P; Plemel D; Herder J; Manifold V; Anderson D
    J Clin Psychol; 1989 Jul; 45(4):513-20. PubMed ID: 2768489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The temporal stability of electrodermal variables over a one-year period in patients with recent-onset schizophrenia and in normal subjects.
    Schell AM; Dawson ME; Nuechterlein KH; Subotnik KL; Ventura J
    Psychophysiology; 2002 Mar; 39(2):124-32. PubMed ID: 12212661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
    Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
    Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing the incremental utility of the negative impression-positive impression differential in detecting simulated personality assessment inventory profiles.
    Hopwood CJ; Talbert CA; Morey LC; Rogers R
    J Clin Psychol; 2008 Mar; 64(3):338-43. PubMed ID: 18302214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capacity to handle unassimilable material: coping strategies of schizophrenics and normals.
    Kaufman G
    J Pers Assess; 1973 Dec; 37(6):519-26. PubMed ID: 4588051
    [No Abstract]   [Full Text] [Related]  

  • 34. [Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].
    Nkam I; Langlois-Thery S; Dollfus S; Petit M
    Encephale; 1997; 23(4):267-72. PubMed ID: 9417392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls.
    Nilsson BM; Hultman CM; Wiesel FA
    Prostaglandins Leukot Essent Fatty Acids; 2006 May; 74(5):339-46. PubMed ID: 16600583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of feigned mental disorders on the personality assessment inventory: a discriminant analysis.
    Rogers R; Sewell KW; Morey LC; Ustad KL
    J Pers Assess; 1996 Dec; 67(3):629-40. PubMed ID: 8938398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrodermal activity as a predictor of schizophrenic relapse.
    Tarrier N; Barrowclough C
    Psychopathology; 1989; 22(6):320-4. PubMed ID: 2639381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Affectivity and alexithymia: two dimensions explicative of the relationship between anxiety and depressive symptoms].
    Bonnet A; Bréjard V; Pasquier A; Pedinielli JL
    Encephale; 2012 Jun; 38(3):187-93. PubMed ID: 22726406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrodermal activity in antidepressant medicated and unmedicated depressive patients and in matched healthy subjects.
    Thorell LH; Kjellman BF; d'Elia G
    Acta Psychiatr Scand; 1987 Dec; 76(6):684-92. PubMed ID: 3442260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrodermal orienting activity in children with Down syndrome.
    Martìnez-Selva JM; Garcìa-Sánchez FA; Florit R
    Am J Ment Retard; 1995 Jul; 100(1):51-8. PubMed ID: 7546636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.